MARKET

BGNE

BGNE

Beigene Ltd
NASDAQ
184.44
-0.40
-0.22%
Opening 10:44 11/29 EST
OPEN
183.08
PREV CLOSE
184.84
HIGH
186.00
LOW
183.08
VOLUME
37.88K
TURNOVER
0
52 WEEK HIGH
280.62
52 WEEK LOW
156.56
MARKET CAP
19.29B
P/E (TTM)
-19.9074
1D
5D
1M
3M
1Y
5Y
Analysts Offer Insights on Healthcare Companies: Merus (MRUS), Structure Therapeutics, Inc. Sponsored ADR (GPCR) and BeiGene (BGNE)
TipRanks · 2d ago
Weekly Report: what happened at BGNE last week (1120-1124)?
Weekly Report · 2d ago
Week In Review: BeiGene Signs $1.3 Billion Deal For Preclinical CDK2 Inhibitor From Boston's Ensem
Beijing's beigene acquires global rights to a preclinical cdk2 inhibitor from boston's ensem therapeutics in a $1.3 billion agreement. Shanghai usynova biopharma out-licenses global rights for its krasg12d inhibitor to astrazeneca in a deal worth up to $419 million. Nanjing simcere acquires greater china rights to an il-4rα inhibitor for atopic dermatitis and asthma.
Seeking Alpha · 3d ago
Analysts Offer Insights on Healthcare Companies: BeiGene (BGNE), Karuna Therapeutics (KRTX) and Theseus Pharmaceuticals (THRX)
TipRanks · 6d ago
BeiGene's multiple myeloma drug gets orphan drug status
U.s. Fda grants orphan drug designation to beigene's sonrotoclax drug candidate for the treatment of relapsed and refractory multiple myeloma. The drug candidate also has the potential to treat b-cell malignancies. Beigene is developing the drug as a combination with brukinsa.
Seeking Alpha · 11/21 17:49
The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics
NASDAQ · 11/21 14:43
BeiGene inks $1.33B deal with Ensem Therapeutics for cancer drug
Healthcare beigene inks $1.33b deal with ensem therapeutics for cancer drug. Beigene agrees to acquire exclusive global license for cancer candidate developed by ensem. Ensem has yet to file an ind for the oral cyclin-dependent kinase 2 (cdk2) inhibitor.
Seeking Alpha · 11/21 12:11
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor
Beigene and ensem therapeutics agree to acquire exclusive global license to cdk2 inhibitor. Beigene is a global biotechnology company. Ensem focuses on difficult-to-drug oncology targets. The drug is an application-ready oral cyclin-dependent kinase 2 inhibitor.
Benzinga · 11/21 11:04
More
About BGNE
BeiGene, Ltd. is a global biotechnology company. The Company is focused on developing and commercializing oncology medicines to improve treatment outcomes and expand access for patients worldwide. The Company has discovered and developed three approved medicines including, BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; tislelizumab, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of PARP1 and PARP2. BRUKINSA is a second-generation small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) designed to maximize BTK occupancy and minimize off-target binding effects. It has obtained approvals to market BRUKINSA in the United States, China, the European Union, the United Kingdom, Canada and Australia. The Company has in-licensed the rights to distribute 13 approved medicines for the China market.

Webull offers Beigene Ltd (ADR) stock information, including NASDAQ: BGNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BGNE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BGNE stock methods without spending real money on the virtual paper trading platform.